search
Back to results

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

Primary Purpose

Brain Injuries, Traumatic, Neurocognitive Disorders, Brain Injuries

Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Tolcapone
Sponsored by
Sheppard Pratt Health System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Brain Injuries, Traumatic

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

TBI and ABI Patients Inclusion Criteria

  • Age 18-70
  • Diagnosis of mild, moderate, or severe TBI, or history of ABI with classification to be made based on parameters at the time of the index event or acquired brain injury.
  • Index event resulting in Traumatic or Acquired Head Injury occurred >12 months prior to trial initiation
  • A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of TBI or ABI
  • Proficient in the English language
  • Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
  • Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the referring Sheppard Pratt physician.
  • Stable medication dose and regimen for 2 months

NCD Patients Inclusion Criteria

  • Age 60-75
  • NCD diagnosed by a Sheppard Pratt physician, per DSM-5
  • No abnormalities on other serum tests to rule out other cause of cognitive impairment: TSH, B12, CBC, Chemistry screen, and RPR.
  • Recent structural neuroimaging (within 1 year or since the time of the onset of cognitive complaint)-noncontrast head CT or MRI-to rule out any gross lesion inconsistent with the diagnosis of MCI (e.g. subdural hematoma, normal pressure hydrocephalus, demyelinating lesion, infarct, or mass lesion)
  • Proficient in the English language
  • A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of NCD
  • Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
  • Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the impression of the referring Sheppard Pratt physician.
  • Stable medication dose and regimen for 2 months

Exclusion Criteria for All Patients:

  • History of, or active, liver disease or abnormal liver function tests--if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST:ALT has exceeded 2:1
  • Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe
  • History of, or active, cardiovascular disease defined as: coronary heart disease, manifested by myocardial infarction, angina pectoris, or heart failure
  • Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic<90mmHg or diastolic<60mmHg Hypertension: Systolic >140mmHg or diastolic>90 mmHg)
  • History of extra-pyramidal symptoms (e.g. tardive dyskinesia, neuroleptic malignant syndrome, or QT prolongation) while on a first-generation anti-psychotic
  • Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe
  • Patient is currently taking tolcapone or any of the following medications that can interact with tolcapone resulting in an adverse events: another COMT inhibitor, benserazide, α-methyldopa, dobutamine, apomorphine, isoproterenol, clozapine, MAO inhibitor
  • Known allergy or serious adverse reaction to tolcapone
  • Participated in any investigational drug trial in the past 30 days.
  • Pregnant or planning to become pregnant during the study period
  • Breastfeeding or planning to breastfeed during the study period.

Other Exclusion Criteria for TBI Patients

• Presence of pre-morbid/pre-TBI cognitive impairment or behavioral dysfunction, as per informant or medical documentation

Sites / Locations

  • Sheppard Pratt Health System

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Open-Label

Arm Description

Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.

Outcomes

Primary Outcome Measures

Change from Baseline Clinical Global Impression Scale (CGI) to two weeks after medication administration

Secondary Outcome Measures

Change from Baseline TBI-QoL to two weeks after medication administration
Questions from the TBI-QoL battery, which consists of tests to assess items on domains of emotion, social activity, physical activity, and cognition
Change from Baseline NIH Toolbox Cognition Battery to two weeks after medication administration
A cognition battery developed by NIH, which consists of tests to assess Executive Function, Attention, Episodic Memory, Language, Processing Speed and Working Memory.

Full Information

First Posted
January 6, 2016
Last Updated
January 17, 2017
Sponsor
Sheppard Pratt Health System
Collaborators
Lieber Institute for Brain Development (LIBD)
search

1. Study Identification

Unique Protocol Identification Number
NCT02652598
Brief Title
Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD
Official Title
A Proof of Concept Open-label Study to Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With Traumatic Brain Injury (TBI), Other Acquired Brain Injuries (ABI), or a Diagnosis of Neurocognitive Disorder (NCD)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 2015 (undefined)
Primary Completion Date
January 2020 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sheppard Pratt Health System
Collaborators
Lieber Institute for Brain Development (LIBD)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The experimental design is an open-label two-week trial of tolcapone to evaluate which clinical domains are affected by tolcapone treatment and to identify "responders" to tolcapone treatment in the two subject groups (BI and NCD)
Detailed Description
Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions. Clinical Instruments for patients: Question banks from large patient-reported outcome measure initiatives will be used and administered and used by computerized-adaptive tests (CATs). These include the TBI-QoL for patients with TBI and question banks from the patient-reported outcome measure information systems (PROMIS) and neurology quality of life measurement initiative (Neuro-QoL). Patients will answer questions related to their mobility, fatigue, pain interference, positive affect and well-being, depression, anxiety, anger and irritability, and emotional and behavioral dyscontrol. Clinical Global Impressions Scale Geriatric Depression Scale-15 State-Trait Anxiety Inventory Hopkins Adult Reading Test Frontal Systems Behavior Scale Montreal Cognitive Assessment Trails A&B Modified Wisconsin Card Sorting Test NIH Toolbox Perceptual Comparison Test Brief Test of Attention Hopkins Verbal Learning Test Brief Visuospatial Memory Test Calibrated Ideational Fluency Assessment Profile of Mood States Digit Span Clinical Instruments for Informants: Neuropsychiatry Inventory Apathy evaluation scale Overt aggression scale Frontal Systems Behavior Scale Laboratory Measures: Blood sample for genotyping Blood sample for assessing COMT activity. Blood sample for a laboratory profile including CBC, CMP, TSH, Hepatitis Panel (B and C), and RPR A urine analysis, urine drug screen, and a urine pregnancy test In addition for NCD patients: a blood sample for tests including Serum Calcium, B12, ESR, and C-reactive protein

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Injuries, Traumatic, Neurocognitive Disorders, Brain Injuries

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Open-Label
Arm Type
Experimental
Arm Description
Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
Intervention Type
Drug
Intervention Name(s)
Tolcapone
Other Intervention Name(s)
Tasmar
Primary Outcome Measure Information:
Title
Change from Baseline Clinical Global Impression Scale (CGI) to two weeks after medication administration
Time Frame
Up to 2 weeks
Secondary Outcome Measure Information:
Title
Change from Baseline TBI-QoL to two weeks after medication administration
Description
Questions from the TBI-QoL battery, which consists of tests to assess items on domains of emotion, social activity, physical activity, and cognition
Time Frame
Up to 2 weeks
Title
Change from Baseline NIH Toolbox Cognition Battery to two weeks after medication administration
Description
A cognition battery developed by NIH, which consists of tests to assess Executive Function, Attention, Episodic Memory, Language, Processing Speed and Working Memory.
Time Frame
Up to 2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
TBI and ABI Patients Inclusion Criteria Age 18-70 Diagnosis of mild, moderate, or severe TBI, or history of ABI with classification to be made based on parameters at the time of the index event or acquired brain injury. Index event resulting in Traumatic or Acquired Head Injury occurred >12 months prior to trial initiation A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of TBI or ABI Proficient in the English language Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the referring Sheppard Pratt physician. Stable medication dose and regimen for 2 months NCD Patients Inclusion Criteria Age 60-75 NCD diagnosed by a Sheppard Pratt physician, per DSM-5 No abnormalities on other serum tests to rule out other cause of cognitive impairment: TSH, B12, CBC, Chemistry screen, and RPR. Recent structural neuroimaging (within 1 year or since the time of the onset of cognitive complaint)-noncontrast head CT or MRI-to rule out any gross lesion inconsistent with the diagnosis of MCI (e.g. subdural hematoma, normal pressure hydrocephalus, demyelinating lesion, infarct, or mass lesion) Proficient in the English language A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of NCD Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the impression of the referring Sheppard Pratt physician. Stable medication dose and regimen for 2 months Exclusion Criteria for All Patients: History of, or active, liver disease or abnormal liver function tests--if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST:ALT has exceeded 2:1 Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe History of, or active, cardiovascular disease defined as: coronary heart disease, manifested by myocardial infarction, angina pectoris, or heart failure Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic<90mmHg or diastolic<60mmHg Hypertension: Systolic >140mmHg or diastolic>90 mmHg) History of extra-pyramidal symptoms (e.g. tardive dyskinesia, neuroleptic malignant syndrome, or QT prolongation) while on a first-generation anti-psychotic Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe Patient is currently taking tolcapone or any of the following medications that can interact with tolcapone resulting in an adverse events: another COMT inhibitor, benserazide, α-methyldopa, dobutamine, apomorphine, isoproterenol, clozapine, MAO inhibitor Known allergy or serious adverse reaction to tolcapone Participated in any investigational drug trial in the past 30 days. Pregnant or planning to become pregnant during the study period Breastfeeding or planning to breastfeed during the study period. Other Exclusion Criteria for TBI Patients • Presence of pre-morbid/pre-TBI cognitive impairment or behavioral dysfunction, as per informant or medical documentation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert J Schloesser, MD
Organizational Affiliation
Sheppard Pratt Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheppard Pratt Health System
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

We'll reach out to this number within 24 hrs